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In this thesis, we focus on h–discrete and h–discrete fractional representa-
tion of a pharmacokinetics-pharmacodynamics (PK-PD) model which describes tumor
growth considering time on hNa, where h > 0. First, we introduce some definitions,
lemmas and theorems on both h–discrete and h–discrete fractional calculus in the
preliminary section. In Chapter 3, we work on the PD model with delay by exam-
ining nabla h–discrete equations and nabla h–discrete fractional equations as well as
variation of constants formulas, accordingly. We introduce our model and solve it
using theorems we proved in the last section of the indicated chapter. When we do
simulation for the solutions we found that jumps occur when drug was given the first
time. Therefore, we decide to work on PD model without delay in Chapter 4. We also
obtain theorems regarding nabla h–discrete equations and nabla h–discrete fractional
equations ignoring delay. We apply our results to the tumor growth model to find
solutions. We observe that jumps disappear on this model once we put new solutions
into code. Although, we do not attain our wanted goal for tumor growth model hav-
ing delay, we decide to write it as a chapter in this thesis because the theorems and
lemmas found in Chapter 3 might be useful for another research work in the future.
In Chapter 5, we give our PK model considering both delay and without delay case,
then solutions of the models are stated accordingly. In the last chapter, we summarize





Discretization in applied mathematics is a procedure which transfers continu-
ous models, functions and equations into discrete form using operators, namely both
delta and nabla operators. Our first aim in starting this process is to make them
appropriate for numerical calculation and implementation on computers. Fractional
calculus studies some various potentials which define the complex number or real num-
ber powers of the differentiation operator and of the integration operator. It has many
applications for fields such as finance, medicine and engineering [29],[3],[7],[9],[10].
Fractionalization of mathematical models in the area of phamacodynamics and
phamacokinetics is not new but it has not really prevailed [30],[33]. Mathematical
complexity is one of the reasons that creates difficulties when numerical methods are
implemented by the users. In clinical setting with populations comprising of several
hundreds of patients, the run-time involved would be a second reason. In paper [3], the
authors worked on PK-PD model starting with discretizing and then fractionalizing.
An explicit solution was found for the indicated model without implementing any
numerical methods. Nevertheless, as the authors stated in their paper [3], some
limitations of the discretization approach appeared in the discrete model for h = 1.
The first property of the tumor growth model, which states that tumor growth
is inhibited while its treatment, fails in simulation process once obtained the solution
is implemented. Simulation demonstrates that as dose is increasing the tumor volume
is increasing in the beginning after decrease is observed in treatment. In discrete
model, the effect of the drug is seen after the day the drug is administrated to the
blood because of the nature of solutions. The graph of the discrete model does not
show any decrease in tumor volume right away after drug administration.
The second property of the model,that tumor volume will never be negative,
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holds true for the discrete model h = 124 on hNh0 but not for h = 1. Tumor volume is
going to be negative while increasing doses significantly. The authors stated in the
paper [3] that this is not reasonable not only from the mathematical side but also
from the biological point of view.
As the authors maintained, the discrete model for h = 1 loses some important
properties that hold true for the continuous model. Our motivation to write this
thesis is based on removing these limitations in the model. While simulation was
done for daily drug concentration, we now consider c(t)-drug concentration values for




In this chapter, we give fundamental theorems, lemmas and definitions on h–
discrete calculus and h–discrete fractional calculus. In order to acquire basic knowl-
edge regarding discrete fractional calculus, we refer [20] to the readers.
Definition 2.1. Let a ∈ R. Nabla operator (∇) which is also known as the backward
difference operator for a function f ∶ Na Ð→ R is defined by
(∇f) (t) ∶= f(t) − f(t − 1),
where Na = {a, a + 1, a + 2, . . .} .
Definition 2.2. Let a ∈ R and h > 0. Nabla h–operator (∇h) which is also known
as the backward h–difference operator for a function f ∶ hNa Ð→ R with a domain




= f(t) − f(t − h)
h
,
where ρh(t) = t − h is backward jump operator on time scale calculus [20].
Definition 2.3. [3] Let α ∈ R. tα is known as a rising factorial power (read as ’t to
the α rising’) is defined by
tα ∶= Γ(t + α)
Γ(t) ,
such that t ∈ R ∖ {...,−2,−1,0}, 0α = 0 and Γ denotes the Gamma function [24].
Definition 2.4. Let α ∈ R and h > 0. The nabla h-factorial of t is defined by
tαh ∶= hα
Γ( th + α)
Γ( th)
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where t ∈ R ∖ {....,−2h,−h,0}, 0αh = 0, and Γ denotes the Gamma function [24].







where α ≥ 0, ρ(t) = t−1, and t ∈ Na. In addition, we recall the definition of α-th order
fractional difference of f which is also known as a Riemann-Liouville (RL) fractional
difference
∇αf(t) ∶= ∇n(∇−(n−α)f(t)),
where α > 0, n − 1 < α < n, n is a positive integer [5].
Definition 2.5 (Nabla h–fractional sum). Let α > 0 and a be any real number. For










f(sh)h, t ∈ hNa.
where h > 0 and ρh(t) = t − h.
Definition 2.6 (Nabla h–fractional difference.). The nabla h–fractional difference of
order α is defined by
(a∇αhf)(t) ∶= (∇nh a∇
−(n−α)
h f)(t), t ∈ hNa.
where a ∈ R, α, h > 0, n − 1 < α < n, and n is a positive integer.
Let us introduce the properties of the rising factorial power functions. While
the proof of the first property is given in [31], we make a generalization and give the
general power rule as a second property.
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Lemma 2.7. Let a be any real number and h > 0, α > 0, µ > 0 be positive numbers.
Whenever the expressions on each side of the equality are valid, these succeeding
properties hold.
(i) ∇htµh = µt
µ−1
h where t ∈ hNa.
(ii) a∇−αh (t − a + h)µh =
Γ(µ + 1)
Γ(µ + α + 1)(t − a + h)
µ+α
h where t ∈ hNa.
Proof. (ii) By using the definition of the nabla h–fractional sum operator, we obtain
















Γ( t−sh+hh + α − 1)
Γ( t−sh+hh )
hµ









Γ( th − s + α)
Γ( th − s + 1)
Γ(s − ah + µ + 1)







Γ( t−ah − s + α)
Γ( t−ah − s + 1)













Γ(s + µ + 1)Γ( t−ah − s + α)
Γ( t−ah + 1)
,
where we used the formula
(u
v
) = Γ(u + 1)
Γ(v + 1)Γ(u − v + 1) ,
where u and v are natural numbers. Next, we apply the following identity given in






)αvβu−v = (α + β)u,













Γ(s + µ + 1)Γ( t−ah − s + α)
Γ( t−ah + 1)
= hα+µ Γ(µ + 1)








)(µ + 1)sα t−ah −s
= hα+µ Γ(µ + 1)
Γ( t−ah + 1)
(µ + 1 + α) t−ah .
Using the definition of nabla rising factorial and nabla h–factorial, we get the following
result which completes the proof.
hα+µ
Γ(µ + 1)
Γ( t−ah + 1)
(µ + 1 + α) t−ah =hα+µ Γ(µ + 1)
Γ( t−ah + 1)
Γ(µ + 1 + α + t−ah )
Γ(µ + 1 + α)
= Γ(µ + 1)
Γ(µ + α + 1)(t − a + h)
µ+α
h .
Theorem 2.8 (Leibniz rule on hNa). Let a be any real number, h > 0, and t ∈ hNa.






















f(t, th − 1)
h
.














f(t − h, s) + f(t − h, t
h












f(t − h, s)
h
+















































f(t, th − 1)
h
.
Subsequently, we introduce the connection between the nabla h– the discrete
operator and the discrete operator. Additionally, we present the relationship between
nabla h–fractional difference operator and the discrete fractional difference opera-
tor. To the best of our knowledge, those connections are not found elsewhere in the
literature.
Lemma 2.9. Let a be any real number, h > 0, and t ∈ hNa. Define the function
k ∶ Na/h Ð→ hNa
k(u) ∶= uh




where u = th ∈ Na/h.
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Proof. Using the definition of nabla operator,
∇hy(t) =
y(t) − y(t − h)
h
we substitute t = uh and obtain ,
∇hy(uh) =
y(uh) − y(uh − h)
h
= y(k(u)) − y(k(u − 1))
h
= ∇(y ○ k)(u)
h
,
where u ∈ Na/h.
Lemma 2.10. Let α,h > 0, a be any real number,and the function k be defined as
k ∶ Na/h Ð→ hNa
k(u) ∶= uh.
And let y ∶ hNa Ð→ R. Then
a∇αhy(uh) = h−α∇αa/h(y ○ k)(u)
where u = th ∈ Na/h.


























Γ(u − s + α)












(u − s + 1)α−1
Γ(α) (y ○ k)(s)
= hα∇−αa/h(y ○ k)(u)
where u ∈ Na/h.

















= h−α∇αa/h(y ○ k)(u)
where u ∈ Na/h.
















THE PHARMACODYNAMICS MODEL WITH DELAY
The pharmacodynamics (PD) is a field that focuses on studying biological
and physiologic effects of drugs, the relation of the effects to drug exposure and the
system of drug movement. Indicated effects can comprise of those observed within
microorganisms, animals, or humans. Main significance in PD is the connecting of
the drug at the receptor (target) since receptors are the most consequential targets
for therapeutic drugs [12, 23].
The main goal of PD modeling is to predict the time curve of the drug effect
potency in natural conditions in health and disease [11]. In the process of discovering
and developing drugs, the PD modeling has been a principal success factor. As an
illustration, optimization of the dosing administration and the delivery profile of new
or presenting drugs can be given which demonstrates that PD modeling has a benefit
as the theoretical basis [13].
Looking back to history, it was discerned that the answer to pharmacological
questions can be found by clinicians and pharmacists employing mathematical mod-
els [14], [15]. Despite this fact, it is significant to emphasize that the development of
the mathematical PD modeling theory was liberated from the mathematical group.
The interpretation of pharmacological concepts in the PD models is the main pivot.
Thus, clinical representation of model parameters can be created and rational model
performance can be used for simulations. Over the past decades, mathematicians
began to make significant contributions to PD modeling with effectual input. Fur-
thermore, a small mathematical group that develops more progressive mathematical
and computational approaches has been established within the PD field [28].
Another important ambition of the PD model is to provide an answer to certain
clinical questions. For the sake of being more precise, it has been shown that the
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attainment of mathematical modeling such as in the biopharma industry is contingent
on acquiring the correct question, correct model, and correct analysis [1]. Ordinary
differential equations play the main role in formulating PD models and they can be
improved in such a way that depends on data which means characterizing existing
data, or in a more mechanistic perspective, where elaborate underlying physiological
mechanisms are depicted [3].
In this chapter, we will consider the PD delayed model for tumor growth. A.
K. Laird [27] started mathematical modeling of tumor growth in the 1960s using the
application of the Gombertz [19] function to fit data from various animals. By ob-
serving the sigmoidal curve, it appeared that the curve fits perfectly to the common
tumor growth behaviour which generally passes through three phases, exponential
growth at the initial step followed by linear growth and ultimately saturation. De-
tailed information concerning the delayed model problem is given in Section 3.3 of
this chapter. In the beginning, the model is given as a system of differential equa-
tions and we use nabla h–discrete and nabla h–discrete fractional operators to write
the model on h–discrete calculus and h–discrete fractional calculus. Therefore, we
introduce the solution of nabla h–discrete equations and its variation of constants
formula in Section 3.1, and the solution of nabla h–discrete fractional equation and
its variation of constants formula in Section 3.2. We present the new tumor growth
model in Section 3.3 and solve it using theorems obtained in the previous sections.
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3.1 Nabla h–Discrete Equations with Delay
Theorem 3.1. Let λ, c, t0 ∈ R. The solution of the following initial value problem
(IVP)
(∇hy)(t) = λy(t − h) for t ∈ hNt0+h
y(t0) = c
is given by
y(t) = c(1 + hλ)
t−t0
h
where h > 0 and hλ ≠ −1.
Proof. By using the definition of the nabla h-discrete operator, we can write
y(t) − y(t − h)
h
= λy(t − h)
y(t) = y(t − h)(1 + hλ).
Setting t = t0 + h, the equation yields
y(t0 + h) = y(t0)(1 + hλ) = c(1 + hλ),
since y(t0) = c. Setting t = t0 + 2h, we have
y(t0 + 2h) = c(1 + hλ)2.
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Proceeding forward gives us
y(t0 + nh) = c(1 + hλ)n for n ∈ N.
The above expression can be rewritten as in the following,
y(t) = c(1 + hλ)
t−t0
h
for all t ∈ hNt0+h and hλ ≠ −1.
Next, we state and prove the variation of constants formula for the non-
homogeneous linear equation.
Theorem 3.2 (Variation of Constants Formula). Assume λ ∈ R ∖ {− 1h} and t0 ∈ R.
Then, the first order nabla h–difference equation
(∇hy)(t) = λy(t − h) + f(t − h) for t = t0 + h, t0 + 2h, ..., (3.1.1)
has the general solution








(1 + hλ) th−s−1f(sh)h
where h > 0 and c ∈ R constant number.
Proof. Using direct substitution of the solution into (3.1.1), we obtain

















































(1 + hλ) th−s−2f(sh)h] + f(t − h)
=λy(t − h) + f(t − h),
where we use Theorem 2.8 (ii) and Theorem 3.1.
3.2 Nabla h–Discrete Fractional Equations with Delay
Theorem 3.3. Let λ, c, t0 ∈ R, h > 0, and α ∈ (0,1). A solution of the following initial
value problem
t0∇αhy(t) = λy(t − h) t = t0 + h, t0 + 2h, ..., (3.2.1)














Γ((n − t0h + 1)α)
.
Proof. We directly substitute the given solution into the equation (3.2.1) and use the




























+1)α−1Γ( t−nh+hh + nα −
t0
h α + α − 1)
Γ((n − t0h + 1)α)Γ( t−nh+hh )
=I.
Using Definition 2.5 and Definition 2.6, we obtain














α+α−1Γ( t−nh+hh + nα −
t0
h α + α − 1)


















α+α−1Γ( sh−nh+hh + nα −
t0
h α + α − 1)
Γ((n − t0h + 1)α)Γ( sh−nh+hh )
.










h−αΓ( t−sh+hh − α)







Γ(s − n + 1 + nα − t0h α + α − 1)










Γ( t−nh−sh+hh − α)







Γ(s + nα − t0h α + α)





















)(1 − α) th−n−s(nα − t0
h
α + α)s,
where we used the formula
(u
v
) = Γ(u + 1)
Γ(v + 1)Γ(u − v + 1) ,






















































)αΓ( th − n + 1 + nα −
t0
h α)














Γ(nα − t0h α + 1)
.



















hα−1Γ(nα − t0h α + 1)













(n − t0h )αλn−
t0




















Γ(nα − t0h α)
,
where we used the definition of rising power factorial and assumption on the Gamma
function,
1




























Γ((n − t0h + 1)α)
= λy(t − h),
as desired.
Subsequently, we give an alternative proof for the initial value problem given
above.
Proof. (Alternative proof.)
We prove above theorems by means of Lemma 2.9 and Lemma 2.10.
The given equation,
t0∇αhy(t) = λy(t − h)
can be written as the following
t0∇αhy(t) =t0 ∇αhy(uh) = h−α∇αt0/h(y ○ k)(u)
λy(t − h) = λy(h(u − 1)) = λ(y ○ k)(u − 1)
∇αt0/h(y ○ k)(u) = λh
α(y ○ k)(u − 1),
where k(u) = uh and u ∈ Nt0/h. Next, we consider the following IVP and its solution
given in [34]
∇νay(t) = λy(t − 1) for t = a + 1, a + 2, a + 3, ...,
∇−(1−ν)0 y(t)∣t=a = y(a) = c.
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Hence, we have
































Γ((n − t0h + 1)α)










)Γ( t−nh+hh + (n −
t0
h + 1)α − 1)















Γ((n − t0h + 1)α)
.















Γ((n − t0h + 1)α)
.
Theorem 3.4 (Variation of Constants Formula). Assume λ, t0 ∈ R and h > 0. The
fractional h–difference equation of order α ∈ (0,1)
t0∇αhy(t) = λy(t − h) + f(t − h) for t = t0 + h, t0 + 2h, ...,
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has the general solution




ŷλ(t + t0 − sh − h, t0)f(sh)hα,














Γ((n − t0h + 1)α)
.













ŷλ(t + t0 − sh − 2h, t0)f(sh)h
α
+ f(t − h).
Using Definition 2.5 and Definition 2.6, we can write the left side of the equation given


























ŷλ(uh + t0 − sh − h, t0)f(sh)h
α+1.










ŷλ(uh + t0 − sh − h, t0)f(sh)h
α+1.
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ŷλ(uh + t0 − sh − h, t0)f(sh)h
α+1
+ f(t − h).










































h ŷλ(t + t0 − sh − h, t0)f(sh)h
α







h ŷλ(t + t0 − sh − h, t0)f(sh)h
α





ŷλ(t + t0 − sh − 2h, t0)f(sh)h
α
+ f(t − h)
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= λy(t − h) + f(t − h).
We use Theorem 3.3 to complete the proof.
3.3 Solving Tumor Growth Model with Delay Using Nabla h–
Discrete and Nabla h–Fractional Operators
As a result of replacement of the unperturbed growth component of PK-PD
model in [25] with the Gombertz growth component, the following form [3] of the
PK-PD model in continuous time was obtained.
x′1(t) = (a − bln(x1(t))x1(t) − k2c(t)x1(t), x1(0) = w0
x′2(t) = k2c(t)x1(t) − k1x2(t), x2(0) = 0
x′3(t) = k1x2(t) − k1x3(t), x3(0) = 0
w(t) = x1(t) + x2(t) + x3(t),
This model describes unperturbed and perturbed tumor growth and consists
of five parameters (w0, a, b, k1, k2) [3]:
• k1 is the transit rate between compartments of the non-proliferating cells.
• a and b control the growth of the proliferating cells.
• w0 is the initial tumor weight.
• k2 is the the potency factor of the drug.
We presume that cells instantaneously cease proliferating depending on drug concen-
tration once affected by drug action and get through certain phases with rate k1 before
21
Figure 3.3.1: Schematic representation of transit compartment model to evaluate
anticancer effect of single therapy.
they die. Considering that non-proliferating cells still give additional weight to total
tumor mass, total tumor w(t) is the sum of proliferating x1 and non-proliferating
tumor cells (x2, x3). But, there are only remaining x1 cells that are proliferating and
not affected by drug action which add to the tumor growth. Here, c(t) is the drug
concentration in plasma and w(t) is total tumor weight.
In the process of constructing the tumor growth inhibition model, two funda-
mental properties are considered [3]:
1. The tumor growth will be prevented while the drug is administrated, i.e. c(t) >
0.
2. The tumor volume will always be positive, i.e. w(t) > 0 for all t ≥ 0.
We first write the delayed model indicated above as nabla h–discrete equations
(∇hu)(t) = a − bu(t − h) − k2c(t − h), x1(0) = w0
(∇hx2)(t) = k2c(t − h)x1(t − h) − k1x2(t − h), x2(0) = 0
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(∇hx3)(t) = k1x2(t − h) − k1x3(t − h), x3(0) = 0
w(t) = x1(t) + x2(t) + x3(t),
where u(t) = lnx1(t).
We solve the above system of difference equations by using Theorem 3.1 and
Theorem 3.2. We obtain the following solutions




























Next, we write the delayed model on h–discrete fractional calculus
∇αhu(t) = a − bu(t − h) − k2c(t − h), x1(0) = w0
∇αhx2(t) = k2c(t − h)x1(t − h) − k1x2(t − h), x2(0) = 0
∇αhx3(t) = k1x2(t − h) − k1x3(t − h), x3(0) = 0
w(t) = x1(t) + x2(t) + x3(t),
where u(t) = lnx1(t).
Using Theorem 3.3 and Theorem 3.4 as tools, we obtain the following solutions
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for x1(t), x2(t), x3(t). We obtain:





















(−b)nhnαΓ( th + nα − n + α)





(−k1)nhnαΓ( th + nα − n + α)
Γ((n + 1)α)Γ( th − n + 1)
.
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3.4 Combination Therapy for Tumor Growth Model with De-
lay
Patients having cancer are widely treated by combination therapy. The princi-
pal purpose of combining anticancer agents in the clinic is to acquire a better reaction
with decreased destructive effects. Starting from early drug development, evaluating
the nature and severity of combination drug therapy in the laboratory has always
been a considerable challenge. A substantial number of reports can be found in the
literature concerning the definition and categorization of pharmacological drug coop-
eration [8], [21]. Furthermore, PK-PD modeling was suggested to quantify in vivo
drug interactions in order to remove these challenging features of combination ther-
apy. Working with this modelling approach gives an opportunity to select the most
advantageous combination therapies [25].
We replace unperturbed growth component given in the paper [25] with the
Gombertz growth component, and we get the model equations for combination ther-
apies in the form of differential equations which are shown below,
x′1(t) = (a − bln(x1(t))x1(t) − (ka2c1(t) + kb2c2(t)ψ)x1(t), x1(0) = w0
x′2(t) = (ka2c1(t) + kb2c2(t)ψ)x1(t) − k1x2(t), x2(0) = 0
x′3(t) = k1x2(t) − k1x3(t), x3(0) = 0
w(t) = x1(t) + x2(t) + x3(t).
Parameters are listed as below,
• k1 is the transit rate between the compartments of the non-proliferating cells.
• ka2 is the potency of the drug A.
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• kb2 is the potency of the drug B.
• c1(t) is the concentration of drug A.
• c2(t) is the concentration of drug B.
It would be worthwhile to mention that ψ was included the model so as to determine
the interaction during joint administration. The value of ψ either greater or less than
1 shows the degree of rise or decrease in the anti-tumor effect. In this section, we first
write the model indicated above as nabla h-discrete equations
(∇hu)(t) = a − bu(t − h) − (ka2c1(t − h) + kb2c2(t − h)ψ), x1(0) = w0
(∇hx2)(t) = (ka2c1(t − h) + kb2c2(t − h)ψ)x1(t − h) − k1x2(t − h), x2(0) = 0
(∇hx3)(t) = k1x2(t − h) − k1x3(t − h), x3(0) = 0
w(t) = x1(t) + x2(t) + x3(t)
where u(t) = lnx1(t).
We solve above system of difference equations by using Theorem 3.1 and The-
orem 3.2. The following solutions are obtained:




























Next, we write the delayed model for combination therapy on h–discrete fractional
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calculus
∇αhu(t) = a − bu(t − h) − (ka2c1(t − h) + kb2c2(t − h)ψ), x1(0) = w0
∇αhx2(t) = (ka2c1(t − h) + kb2c2(t − h)ψ)x1(t − h) − k1x2(t − h), x2(0) = 0
∇αhx3(t) = k1x2(t − h) − k1x3(t − h), x3(0) = 0
w(t) = x1(t) + x2(t) + x3(t),
where u(t) = lnx1(t).
Using Theorem 3.3 and Theorem 3.4 as tools, we obtain the following solutions
for x1(t), x2(t), x3(t). We obtain:





















(−b)nhnαΓ( th + nα − n + α)





(−k1)nhnαΓ( th + nα − n + α)




THE PHARMACODYNAMICS MODEL WITHOUT DELAY
Even though we get solutions for delay case of our model, try different drug
doses, do parameter estimations and simulations, we still see jumps on the graph.
Therefore, in this chapter, we investigate our tumor growth model by getting rid of
delay from model equations. In order to obtain solutions for indicated problem, we
first introduce several theorems including variation of constants formulas for nabla
h–discrete and discrete fractional equations by neglecting delay. In the final section,
we solve our model which does not have delay with help of those theorems we prove
in Section 4.1 and Section 4.2. As a result, we are able to eliminate occurring jumps
from graph for tumor growth model without delay.
4.1 Nabla h–Discrete Equations without Delay
Theorem 4.1. Let h > 0 and λ, c, t0 ∈ R be constants. The solution of the following
initial value problem (IVP)
(∇hy)(t) = −λy(t) for t ∈ hNt0 (4.1.1)
y(t0) = c (4.1.2)
is given by
y(t) = c(1 + hλ)−
t−t0
h
where hλ ≠ −1.
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Proof. By using the definition of nabla h-discrete operator, we can write
y(t) − y(t − h)
h
= −λy(t)
y(t) = y(t − h)(1 + hλ)−1.
Setting t = t0 + h, the equation yields
y(t0 + h) = y(t0)(1 + hλ)−1 = c(1 + hλ)−1
since y(t0) = c. Setting t = t0 + 2h, we have
y(t0 + 2h) = c(1 + hλ)−2.
Proceeding forward gives us
y(t0 + nh) = c(1 + hλ)−n for n ∈ N.
The above expression can be rewritten as follows ,
y(t) = c(1 + hλ)−
t−t0
h
for all t ∈ hNt0 and hλ ≠ −1.
Next, we give variation of constants formula for the equation 4.1.1 and its
proof.




are any real numbers. Then, the first order nabla h–difference equation
(∇hy)(t) = −λy(t) + f(t) for t = t0, t0 + h, t0 + 2h, ..., (4.1.3)
has the general solution







(1 + hλ)−( th−s+1)f(sh)h
where c ∈ R constant number.
Proof. Using direct substitution into (4.1.3), we obtain







(1 + hλ)−( th−s+1)f(sh)h

























−λ(1 + hλ)−( th−s+1)f(sh)h + f(t)







(1 + hλ)−( th−s+1)f(sh)h] + f(t)
= − λy(t) + f(t),
where we use Theorem 2.8 (i) and Theorem 4.1.
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4.2 Nabla h–Discrete Fractional Equations without Delay
Theorem 4.3. Let h > 0, λ, c ∈ R. and α ∈ (0,1). A solution of the following initial
value problem
t0∇αhy(t) = −λy(t) t = t0, t0 + h, t0 + 2h, ..., (4.2.1)
y(t0) = c (4.2.2)
is given by














Γ((n − t0h + 1)α)
where ∣λhα∣ < 1.
Proof. We directly substitute the given solution into the equation (4.2.1) and use



























α+α−1Γ( t−t0+hh + nα −
t0
h α + α − 1)





Using Definition 2.5 and Definition 2.6, we obtain
I =∇h t0∇
−(1−α)









αΓ( t−t0h + nα −
t0
h α + α)

















αΓ( sh−t0h + nα −
t0
h α + α)







h−α Γ( t−sh+hh − α)










Γ(s − t0h + 1)
×
Γ(s − t0h + nα −
t0
h α + α)





Γ( th − s + 1 − α)










Γ(s − t0h + 1)
×
Γ(s − t0h + nα −
t0
h α + α)
Γ((n − t0h + 1)α)
.
Subsequently, we interchange the order of summation and get












−1)α+1Γ(s − t0h + (n −
t0
h + 1)α)




Γ( th − s + 1 − α)














−1)α+1Γ(s + (n − t0h + 1)α)
Γ(s + 1)Γ((n − t0h + 1)α)
×
Γ( th − s −
t0
h + 1 − α)
Γ( th − s −
t0
h + 1)Γ(1 − α)
.
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Next, we apply the following formulas
(u
v
) = Γ(u + 1)
Γ(v + 1)Γ(u − v + 1) ,

















































Γ( t−t0h + 1)





















Γ(1 + nα − t0h α)
.
Now we use Definition 2.3 and Definition 2.4,













Γ( t−t0h + 1 + nα −
t0
h α)


















Γ(1 + nα − t0h α)
.
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Using Lemma 2.7 (i), the following is obtained































Γ(nα − t0h α)
since
1
Γ(0) = 0. Hence we have














Γ((n + 1)α − t0h α)














Γ((n − t0h + 1)α)
= − λy(t)
as desired.








= −λ(y ○ k)(u)
∇αt0/h(y ○ k)(u) = −λh
α(y ○ k)(u)
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where k(u) = uh = t and u ∈ Nt0/h. We use solution of the following IVP given in [4]
∇αy(t) = −λy(t) for t = 1,2,3, ...,
y(0) = c
Hence we have,










Γ((n − t0h + 1)α)










Γ((n − t0h + 1)α)










Γ((n − t0h + 1)α)
Now we use Definition 2.3 and rewrite the equation






h Γ( t−t0+hh + 1 + nα −
t0
h α + α − 1)





















































Γ((n − t0h + 1)α)
.
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Theorem 4.4 (Variation of Constants Formula). Assume h > 0 and λ, c, t0 ∈ R. The
fractional difference equation of order α ∈ (0,1)
t0∇αhy(t) = −λy(t) + f(t)) t = t0, t0 + h, t0 + 2h, ..., (4.2.3)
has the general solution




y∗λ(t + t0 − sh, t0)f(sh)hα















Γ((n − t0h + 1)α)
.




y∗λ(t + t0 − sh, t0)f(sh)hα









































































































































Γ((n − t0h + 1)α)
f(sh)h2








































Γ((n − t0h + 1)α)
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Γ((n − t0h + 1)α − 1 + 1)
Γ((n − t0h + 1)α − 1 + 1 + 1 − α)


































































































h f(t) + f(t)
= − λyp(t) + f(t).
We use Theorem 4.3 to complete the proof.
38
Now, we focus on the following problem,
t0∇αhy(t) = −λy(t) t = t0, t0 + h, t0 + 2h, ..., (4.2.4)
y(t0) = 1 (4.2.5)
We define the solution of (4.2.4)-(4.2.5) as indicated below,














Γ((n − t0h + 1)α)
Theorem 4.5. Let 0 < α < 1 . The following are valid:
(i) êα(−λ,0) = 1, t ∈ hNa.
(ii) t0∇αh êα(−λ, (t − t0)αh) = −λêα(−λ, (t − t0)αh), t ∈ hNa.
(iii) êα(−λ, (t − t0)αh) ≥ 0, t ∈ hNa.
(iv) êα(0, (t − t0)αh) =
(t − t0 + h)α−1
Γ(α)hα−1 , t ∈ hNa.
(v) êα(−λ, (t − t0)αh) converges absolutely if ∣λhα∣ < 1.














Γ((n − t0h + 1)α)












Γ(1)Γ((n − t0h + 1)α)














(−λhα)n = (1 + λhα) 1(1 + λhα) = 1
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(ii) We first use the definition of êα(−λ, (t − t0)αh),




(t − t0 + h)α−1h
Γ(α) )




























(t − t0 + h)α−1h
Γ(α) )

















Γ((n − t0h + 1)α)
=I
where we used Definition 2.6.
Next, we use Lemma 2.7 (ii) and obtain the following,




Γ(α − 1 + 1)(t − t0 + h)α−1+1−αh
Γ(α − 1 + 1 + 1 − α)Γ(α) )


























Subsequently, Lemma 2.7 (i) is used as a tool. We simplify and get,

































Γ((n − t0h + 1)α)
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Γ((n − t0h + 1)α)
= − λêα(−λ, (t − t0)αh)
(iii) In order to prove third property, we plug in the solution into the equation 4.2.4.
Using Definition 2.6, the following is obtained
t0∇αh êα(−λ, (t − t0)αh) =(∇h t0∇
−(1−α)





(t − sh + h)−αh








∇h(t − sh + h)−αh êα(−λ, (sh − t0)αh)h
+ (t − sh + h)
−α
h êα(−λ, (sh − t0)αh)h
Γ(1 − α)h ∣t→t−h,s→ th = I
where we use Theorem 2.8 (i).
















(t − sh + h)−α−1h êα(−λ, (sh − t0)αh)h


















= −λêα(−λ, (t − t0)αh)






(t − sh + h)−α−1h êα(−λ, (sh − t0)αh)h +
−αΓ(−α)h−α−1
Γ(1 − α)Γ(1) êα(−λ, (t − t0)
α
hh)
= −λêα(−λ, (t − t0)αh)






(t − sh + h)−α−1h êα(−λ, (sh − t0)αh)h + êα(−λ, (t − t0)αh)h−α
= −λêα(−λ, (t − t0)αh)
êα(−λ, (t − t0)αh) =
α




(t − sh + h)−α−1h êα(−λ, (sh − t0)αh)
Since 0 < α < 1 and ∣λhα∣ < 1, it is obvious that (λ + h−α) > 0 and Γ(1 − α) > 0. Using
Definition 2.4, we can show that
(t − sh + h)−α−1h =
h−α−1Γ( th − s − α)
Γ( th − s + 1)
≥ 0
for t0 ≤ sh ≤ t − h. Thus, using the fact that êα(−λ,0) = 1, we obtained
êα(−λ, (t − t0)α) ≥ 0 t ∈ hNt0 .
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(iv) We first rewrite the solution of 4.2.4-4.2.5 as the following,














Γ((n − t0h + 1)α)























set λ = 0
êα(0, (t − t0)αh) =
(t − t0 + h)α−1h
hα−1Γ(α) .
We write generalization of the theorem given in the paper [16]. If we take h = 1, we
obtain the result shown in the paper indicated above.
(v) We prove that t0∇αh êα(−λ, (t − t0)αh) is convergent using the ratio test. We will





where α ∈ R. Then
lim
n→∞
Γ( t−t0h + (n + 2 −
t0
h )α)











Γ((n − t0h + 1)α)((n −
t0
h + 1)α)α

















Γ((n − t0h + 1)α)













h Γ((n − t0h + 1)α)







































Γ((n − t0h + 2)α)Γ(
t−t0







Γ( t−t0h + (n + 2 −
t0
h )α)








Γ((n − t0h + 1)α)((n −
t0
h + 1)α)α
Γ((n + 1 − t0h + 1)α)
⋅
( t−t0h + (n + 1 −
t0
h )α)α





( t−t0h + (n + 1 −
t0
h )α)α





∣ = ∣λhα∣ < 1,
where we used (4.2.6)-(4.2.7) and Definition 2.4.
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4.3 Solving Tumor Growth Model without Delay Using Nabla
h–Discrete and Nabla h–Fractional Operators
In this section, we give solutions to the model given in Section 3.3 but without
the delay condition. We first write the model on h–discrete calculus as the following
(∇hu)(t) = a − bu(t) − k2c(t), x1(0) = w0
(∇hx2)(t) = k2c(t)x1(t) − k1x2(t), x2(0) = 0
(∇hx3)(t) = k1x2(t) − k1x3(t), x3(0) = 0
w(t) = x1(t) + x2(t) + x3(t),
where u(t) = lnx1(t).
Using Theorem 4.1 and Theorem 4.2, we obtain the following solutions
u(t) = u(0) 1
































Next, we write the representation of our model on h–discrete fractional calculus
below
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∇αhu(t) = a − bu(t) − k2c(t), x1(0) = w0
∇αhx2(t) = k2c(t)x1(t) − k1x2(t), x2(0) = 0
∇αhx3(t) = k1x2(t) − k1x3(t), x3(0) = 0
w(t) = x1(t) + x2(t) + x3(t),
where u(t) = lnx1(t).
Then, we solve the model utilizing Theorem 4.3 and Theorem 4.4 and get the
following outcome























(−b)nhnαΓ( th + nα + α)






(−k1)nhnαΓ( th + nα + α)
Γ((n + 1)α)Γ( th + 1)
.
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4.4 Combination Therapy for Tumor Growth without Delay
Model
In this section, we focus on the tumor growth model for without delay form
for combination therapy as we did in Section 3.4. First, we write the model on h–
discrete calculus. Then we introduce solutions using theorems we present in Section
4.1. Moreover, we continue to write our model on h–fractional calculus and give its
solutions.
(∇hu)(t) = a − bu(t) − (ka2c1(t) + kb2c2(t)ψ), x1(0) = w0
(∇hx2)(t) = (ka2c1(t) + kb2c2(t)ψ)x1(t) − k1x2(t), x2(0) = 0
(∇hx3)(t) = k1x2(t) − k1x3(t), x3(0) = 0
w(t) = x1(t) + x2(t) + x3(t)
where u(t) = lnx1(t).
Using Theorem 4.1 and Theorem 4.2, we obtain the following solutions
u(t) = u(0) 1







(1 + hb) th−s+1
























Next, we write the representation of our model on h–discrete fractional calculus below
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∇αhu(t) = a − bu(t) − (ka2c1(t) + kb2c2(t)ψ), x1(0) = w0
∇αhx2(t) = (ka2c1(t) + kb2c2(t)ψ)x1(t) − k1x2(t), x2(0) = 0
∇αhx3(t) = k1x2(t) − k1x3(t), x3(0) = 0
w(t) = x1(t) + x2(t) + x3(t),
where u(t) = lnx1(t).
As a following step, we solve the model with help of Theorem 4.3 and Theorem
4.4 and get the following result
























(−b)nhnαΓ( th + nα + α)






(−k1)nhnαΓ( th + nα + α)





Pharmacokinetics (PK) is one of the fields of pharmacology which studies
the behaviour of the drugs that are administrated to the body over time. To put
another way, PK determines the fate of substances given to a living organism. These
substances include pesticides, cosmetics, pharmaceutical drugs, food additives, and
so on. Clinical pharmacokinetics [17] is the application of pharmacokinetic rules to
the secure and productive therapeutic control of drugs in an single patient. It forms a
reasonable basis for administrating proper amounts of the drug for a sensible amount
of time to attain desired beneficial effects while minimizing detrimental events. PK’s
aim is to analyze chemical metabolism and to uncover the future of a chemical from
the time it is administered till the moment it is completely removed from the body.
The PK model consists of the following the processes: liberation, absorption,
distribution, metabolism, and elimination of a drug [18]. Liberation is the procedure
that pharmaceutical formulation release drug. Absorption is the procedure in which
the substance enters to blood circulation. Distribution is the process whereby sub-
stances circulate or diffuse throughout fluids and tissues of the body. Metabolism or
biotransformation is the process whereby an organism recognizes a foreign substance
is present. Elimination or excretion is the removal of substances from the body.
Patient-related factors and a drug’s chemical properties define the pharma-
cokinetics of the drug. With the aim of predicting pharmacokinetics parameters in
populations some patient-related factors such as renal function, sex and age can be
used. For instance, some drugs, especially those demanding both metabolism and
excretion are noticeably long in the elderly.
In 1937, Swedish physiologist T. Teorell [32] published first pharmacokinetic
model which describes the circulatory system. In addition, F. H. Dost who was a
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German pediatrist is considered to be the founder of the term pharmacokinetic, we
refer the reader to [35] for further information. “Der Blutspiegel” [14] in 1953 and
“Grundlagen der Pharmakokinetik” [15] in 1968 were two of his famous books in
which he gave elaborate information and detailed analysis concerning drug behavior
in time based on a linear differential equation [23].
The drug concentration in blood within given time is measured in pharma-
cokinetic experiments. For the sake of improving the PK model, the body is usually
divided into several parts. In this chapter, we focus on a two-compartment model
approach which is broadly used. The model is based on linear differential equations
and from a modeling perspective forms a verifiable method to determine the drug
concentration. The time curve of many drugs can be represented by such models.
In this chapter, we first introduce our tumor pharmacokinetic model with two
compartments. Subsequently, we consider model for delay and without delay cases.
We give solutions for two forms of the models in the final section of this chapter,
accordingly.
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5.1 Two-Compartment PK Model without Delay
In this section, we consider two-compartment pharmacokinetic model. We
study oral absorption and endovenous control of the drug. Blood samples have to
be taken from patients in order to measure drug concentration. However, existence
of data is restricted due to moral limits. It is observed that two compartments are
adequate to suitably illustrate the time curve in blood for most drugs. To acquire
more knowledge regarding it, we refer the reader to [18].
A two-compartment model should be comprise of two physiological sensible
parts [26]:
• The main compartment is recognized with the blood and organs greatly provided
with blood like liver or kidney.
• The peripheral compartment represents as an illustration tissue or typically, the
section of the body which is severely supplied with blood.
The compartments are linked with each other and thus sharing between main and
peripheral compartments occurs. Essential assumptions in pharmacokinetics are as
follows:
• The drug is completely removed (metabolism and excretion) from the body via
the main compartment.
Now we give our two-compartment tumor growth PK model.
A′(t) = −kaA(t), A(tD) = f ∗ dose
C ′(t) = ka
A(t)
V
− (kel + k12)C(t) + k21P (t), C(tD) = 0
P ′(t) = k12C(t) − k21P (t), P (tD) = 0
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where 0 < f ≤ 1 is a parameter describing the amount of drug which reaches the blood.
Without loss of generality, we take f = 1. The model has the parameters
µ = (ka, kel, k12, k21)
and dose as a variable.
• V is volume of distribution in the model.
• ka > 0 is absorption rate constant.
• kel > 0 is elimination rate from the body.
• k12, k21 > 0 stand for the distribution between main and peripheral compart-
ment.
• C(t) is the drug concentration in the blood.
• A(t) is the absorption amount.
It is worthwhile to mention that while for the two-compartment model k12, k21 > 0,
for the one compartment model k12 = k21 = 0.
As it is seen above, the model is given in the form of differential equations and
our aim is to find the solution by rewriting the model as a nabla h–discrete equation.




− (kel + k12)C(t) + k21P (t), C(tD) = 0
∇hP (t) = k12C(t) − k21P (t), P (tD) = 0
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In order to find the solution for nabla h–discrete equations indicated above,
we use theorems that we prove in Section 4.1 and Section 4.2. Using Theorem 4.1,
we obtain the solution of the first equation as follows,
A(t) = dose ⋅ (1 + hka)−
t−tD
h .





































where M is an 2 × 2 matrix and I is an 2 × 2 identity matrix.
M =
⎡⎢⎢⎢⎢⎢⎢⎣
−(kel + k12) k21
k12 −k21
⎤⎥⎥⎥⎥⎥⎥⎦
The characteristic equation for matrix M is
λ2 + (kel + k12 + k21)λ + kelk21 = 0.
Our eigenvalues are
λ1 =
−(kel + k12 + k21) +
√




−(kel + k12 + k21) −
√
(kel + k12 + k21)2 − 4kelk21
2
.
Next step is to use the Putzer algorithm in order to achieve solution; therefore,
we introduce the Putzer algorithm for delayed form equation.
Theorem 5.1. The unique solution of the initial value problem
∇hy(t) = Ay(t) t = t0 + h, t0 + 2h, ..., (5.1.2)
y(t0) = c (5.1.3)
is given by
y(t) = (I − hA)−
t−t0
h c
where A is an n × n constant matrix, and c and y(t) are n × 1 vectors.
Now, we define the following nabla function
y∗A(t, t0) ∶= (I − hA)−
t−t0
h (5.1.4)
Theorem 5.2 (Variation of Constants Formula). Assume t0 ∈ R and h > 0. The
fractional h–difference equation
∇hy(t) = Ay(t) + f(t) for t = t0 + h, t0 + 2h, ...,
has the general solution




y∗A(t + t0 − sh + h, t0)f(sh)h
where A is an n × n constant matrix, c is n × 1 vector.
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Next, we introduce the Putzer Algorithm on h–discrete calculus. The indicated
algorithm is a method used for calculating matrix exponential functions analytically
using eigenvalues and components in the solution of a simple linear system. Hence,
we first introduce the matrix exponential function.
Definition 5.3. (Matrix Exponential Function without Delay) Let A be an n × n
constant matrix. The unique matrix valued solution of the initial value problem(IVP)
∇hY (t) = AY (t) for t ∈ hNa (5.1.5)
Y (a) = In, (5.1.6)
where In denotes the n × n identity matrix, is called the matrix exponential function.
Now, we introduce the theorem regarding the Putzer algorithm and its proof
for h–discrete calculus.
Theorem 5.4. Let λ1, λ2, ..., λn be (not necessarily distinct) eigenvalues of the n × n








Mi = (A − λiIn)Mi−1, (1 ≤ i ≤ n − 1)
Mn = 0










is the solution of the initial value problem
∇hp(t) =
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
λ1 0 0 ⋯ 0
1 λ2 0 ⋯ 0
0 1 λ3 ⋯ 0
⋮ ⋱ ⋱ ⋱ ⋮
0 ⋯ 0 1 λn
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦














pi+1(t)Mi. Firstly, we show that Φ solves the IVP (5.1.5)-
(5.1.6). It is good to demonstrate that
Φ(a) = p1(a)M0 + p2(a)M1 +⋯ + pn(a)Mn−1
= In
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since the given initial values p(a) = [1 0 0 ⋯ 0]
T
.














since ∇h is a linear operator. Subsequently, we use (5.1.7) and obtain
∇hΦ(t) −AΦ(t) = λ1p1(t)M0 + [p1(t) + λ2p2(t)]M1 + [p2(t) + λ3p3(t)]M2





= [λ1M0 +M1 −AM0]p1(t) + [λ2M1 +M2 −AM1]p2(t)
+⋯ + [λnMn−1 −AMn−1]pn(t)
= [λnIn −A]Mn−1pn(t),
since Mi = (A − λiIn)Mi−1 for (1 ≤ i ≤ n). Using the Cayley-Hamilton Theorem, we
get zero for the last quantity.
In other words,
(λnIn −A)Mn−1pn(t) = −(A − λnIn)(A − λn−1In)⋯(A − λ1In)pn(t)
= 0n×n.
Since y∗A,(t, a) satisfies the IVP (5.1.5)-(5.1.6), we have
Φ(t) = y∗A(t, a)
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by the unique solution of the given initial value problem.



















−(kel + k12 + λ1) k21
k12 −(k21 + λ1)
⎤⎥⎥⎥⎥⎥⎥⎦
.


























Next, y2(t) is a solution of the IVP






















−(kel + k12 + λ1) k21







































where we use Definition 2.1 as a tool.
Next, we apply integration by parts formula given in Theorem 2.11 to the last
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equality and we obtain,
Q = 1
λ1









































) + (1 − hλ1)λ2(1 − hλ2)λ1
Q
Q = (1 − hλ1)
− t





We plug in result into equation 5.1.9 and obtain









+ (1 − hλ1)
− t





−(kel + k12 + λ1) k21
k12 −(k21 + λ1)
⎤⎥⎥⎥⎥⎥⎥⎦
Finally, we rewrite equation 5.1.1 and the following result is achieved




























































since ∇(1 + hka)(−s+
tD
h

















Successively, we apply Theorem 2.11 to the last equality and get the following outcome





) (1 − hλ1)−(
t
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We simplify and obtain














− λ1(1 + hka)
ka(1 − hλ1)
I
















































































=dose ⋅ ka ⋅ k12











− dose ⋅ ka ⋅ k12











From previous calculation, more precisely, using Equation 5.1.11 and Equation 5.1.12,
the following result is obtained
P (t) = dose ⋅ ka ⋅ k12








− dose ⋅ ka ⋅ k12









5.2 Two-Compartment PK Model with Delay
In this section, we analyze the model shown in Section 5.1 but in the delay
case. Firstly, we write the model for the nabla h–discrete calculus. Then, we use
theorems which we proved in Section 3.1 and Section 3.2. Furthermore, we use the
definition of eMt where M is n×n matrix and the Putzer algoritm for the solution of
the delayed two-compartment PK model.
We first introduce the Putzer algorithm for the delayed form equations. So,
we state the subsequent theorem and the proof follows similar techniques as Theorem
3.3.
Theorem 5.5. The unique solution of the initial value problem
∇hy(t) = Ay(t − h) t = t0 + h, t0 + 2h, ..., (5.2.1)
y(t0) = c (5.2.2)
is given by
y(t) = (I + hA)
t−t0
h c
where A is an n × n constant matrix, c and y(t) are n × 1 vectors.
Now, we define the following nabla function
ŷA(t, t0) ∶= (I + hA)
t−t0
h (5.2.3)
Theorem 5.6 (Variation of Constants Formula). Assume t0 ∈ R and h > 0. The
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fractional h–difference equation
∇hy(t) = Ay(t − h) + f(t − h) for t = t0 + h, t0 + 2h, ...,
has the general solution




ŷA(t + t0 − sh − h, t0)f(sh)h,
where A is an n × n constant matrix, c is n × 1 vector.
Definition 5.7. (Matrix Exponential Function with Delay) Let A be an n×n constant
matrix. The unique matrix valued solution of the initial value problem(IVP)
∇hY (t) = AY (t − h) for t ∈ hNa (5.2.4)
Y (a) = In, (5.2.5)
where In denotes the n × n identity matrix, is called the matrix exponential function.
Now, we introduce theorem regarding the Putzer algorithm and its proof.
Theorem 5.8. Let λ1, λ2, ..., λn are (not necessarily distinct) eigenvalues of the n×n








Mi = (A − λiIn)Mi−1, (1 ≤ i ≤ n − 1)
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Mn = 0









is the solution of the initial value problem
∇hp(t) =
⎡⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎢⎣
λ1 0 0 ⋯ 0
1 λ2 0 ⋯ 0
0 1 λ3 ⋯ 0
⋮ ⋱ ⋱ ⋱ ⋮
0 ⋯ 0 1 λn
⎤⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎥⎦














pi+1(t)Mi. Firstly, we show that Φ solves the IVP (5.2.4)-
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(5.2.5). It is good to demonstrate that
Φ(a) = p1(a)M0 + p2(a)M1 +⋯ + pn(a)Mn−1
= In
since the given initial values p(a) = [1 0 0 ⋯ 0]
T
.














since ∇h is a linear operator. Subsequently, we use (5.2.6) and obtain
∇hΦ(t) −AΦ(t − h) = λ1p1(t − 1)M0 + [p1(t − h) + λ2p2(t − h)]M1






= [λ1M0 +M1 −AM0]p1(t − h) + [λ2M1 +M2 −AM1]p2(t − h)
+⋯ + [λnMn−1 −AMn−1]pn(t − h)
= [λnIn −A]Mn−1pn(t − h),
since Mi = (A − λiIn)Mi−1 for (1 ≤ i ≤ n). Using Cayley-Hamilton Theorem, we get
zero for the last quantity.
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In other words,
(λnIn −A)Mn−1pn(t − h) = −(A − λnIn)(A − λn−1In)⋯(A − λ1In)pn(t − h)
= 0n×n.
Since ŷA,(t, a) satisfies the IVP (5.2.4)-(5.2.5), we have
Φ(t) = ŷA(t, a)
by the unique solution of the given initial value problem.
Now, we first rewrite our tumor growth PK model by taking delay into con-
sideration.




− (kel + k12)C(t − h) + k21P (t − h), C(tD) = 0
∇hP (t) = k12C(t − h) − k21P (t − h), P (tD) = 0
From first equation, we obtain a solution for A(t) as follows
A(t) = dose ⋅ (1 − hka)
t−tD
h .







































where M is an 2 × 2 matrix and I is 2 × 2 identity matrix.
M =
⎡⎢⎢⎢⎢⎢⎢⎣
−(kel + k12) k21
k12 −k21
⎤⎥⎥⎥⎥⎥⎥⎦
and we use definition of eMt. The characteristic equation for matrix M is
λ2 + (kel + k12 + k21)λ + kelk21 = 0.
Our eigenvalues are
λ1 =
−(kel + k12 + k21) +
√
(kel + k12 + k21)2 − 4kelk21
2
λ2 =
−(kel + k12 + k21) −
√
(kel + k12 + k21)2 − 4kelk21
2
.



















−(kel + k12 + λ1) k21





















So, n1(t) is a solution of IVP
∇hn1(t) = λ1n1(t − h)
n1(0) = 1
and we obtain
n1(t) = (1 + hλ1)
t
h .
Next, n2(t) is a solution of IVP























−(kel + k12 + λ1) k21


























−s−1) (1 + hλ1)
hλ1
∇(1 + hλ1)sh









where we use Definition 2.1 as a tool.
Subsequently, we apply Theorem 2.11 to last equality and we obtain,





















We simplify and get the following result

























L = (1 + hλ1)
t






We plug this result into equation 5.2.9 and obtain









+ (1 + hλ1)
t





−(kel + k12 + λ1) k21
k12 −(k21 + λ1)
⎤⎥⎥⎥⎥⎥⎥⎦
Consequently, we rewrite equation 5.2.8 and the following result is achieved



























































since ∇(1 − hka)(s−
tD
h

















Successively, we apply Theorem 2.11 to last equality and get the following outcome





) (1 + hλ1)(
t
h















































We simplify and obtain















































Hence, we obtain solution of C(t). Thus,















































=dose ⋅ ka ⋅ k12











− dose ⋅ ka ⋅ k12











From previous calculation, more precisely, using Equation 5.2.11 and Equation 5.2.12,
the following result is obtained
P (t) = dose ⋅ ka ⋅ k12








− dose ⋅ ka ⋅ k12









5.3 Application of the Pharmacokinetics Model
In this section, we illustrate an example where one can see how we do calcu-
late the concentration over time. A drug is administered to the body daily in four
consecutive days at the times t = 360,384,408,432. We calculate the concentration
in the following way:
Before the drug is administered, there is no concentration. So we have
C(t) = 0 for t < 360.
After the first dose is given at t = 360, we define
C1(t) ∶= C(t, dose1) for t ∈ N360
Subsequently, a second dose is administered to the body at t = 384. The concentration
includes two parts: the first part is the remaining concentration from the first dose
and the second part is the concentration due to the second dose.
C2(t) ∶= C1(t) +C(t, dose2) for t ∈ N384
Finally, a third dose is administered at time t = 408. Now, we consider two parts in
order to determine drug concentration in the blood: the first part is the remaining
concentration from the first and the second doses, namely C2(t), the second part is
the concentration due to the third dose.
C3(t) ∶= C2(t) +C(t, dose3) t ∈ N408
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We continue to the process and write
C4(t) ∶= C3(t) +C(t, dose4) for t ∈ N432 .
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Chapter 6
CONCLUSION AND FUTURE WORK
In this thesis, we worked on h–discrete calculus and h–discrete fractional cal-
culus for the sake of finding solutions to our tumor growth model for both mono and
combination therapies. To put it another way, we first introduced some basics and
fundamental knowledge about h–discrete calculus and h–discrete fractional calculus
as preliminaries. We then focus on the nabla h–discrete equation for delayed form and
introduce the variation of constants formula accordingly. Following to this, we exam-
ine h–discrete fractional equation with delay and its variation of constants formula,
too. We write our tumor growth model for both mono and combination therapies and
find solutions for them in Chapter 3. Since our aim was to eliminate jumps from our
tumor growth model’s graph, as a following step we applied the same procedure for
the model not having delay in Chapter 4 and we achieve our goal,in other words, we
are able to remove those jumps from our tumor growth graph. In the last chapter, we
consider PK model. Furthermore, we write the PK model on h–discrete calculus and
find solutions for it. In order to obtain solutions we had to use the Putzer algorithm,
therefore, we introduced the Putzer algorithm on h–discrete calculus. We give an
application of PK model in the final section of Chapter 5.
In future work, we would like to fractionalize PK model and examine its effects
for parameter estimations as well. Additionally, we will work on our PK model for
combination therapy on both h–discrete calculus and h–discrete fractional calculus.
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laufflüssigkeit, Leipzig, Thieme, 1953.
[15] F. H. Dost, Grundlagen der Pharmakokinetic, Stuttgart, Thieme, 1968.
[16] P. W. Eloe, J. Jonnalagadda, Mittag-Leffler stability of the systems of
fractional nabla difference equations, Bulletin of the Korean Mathematical Society,
56 (2019), 977-992.
[17] E. Flynn, Clinical Pharmacokinetics, Elsevier Inc, 2007.
[18] J. Gabrielsson, D. Weiner, Pharmacokinetic and pharmacodynamic data
analysis: Concepts and applications, Swedish Pharmaceutical Press, Stockholm,
2006.
78
[19] B. Gompertz, On the nature of the function expressive of the law of human
mortality, and on a new mode of determining the value of life contingencies, Philos.
Trans. R. Soc. Lond., 115 (1825), 513–585.
[20] C. Goodrich and A.C. Peterson, Discrete Fractional Calculus, Springer
International Publishing, 2015.
[21] W. R. Greco, G. Bravo, J. C. Parsons, The search for synergy: a critical
review from a response surface perspective, Pharmacol Rev 47(1995), 331–385.
[22] M. Gurses, G. S. Guseinov, B. Silindir, Integrable equations on time
scales, J. Math. Phys., 46 (2005), 1–22.
[23] G. Koch and J. Schropp, Mathematical concepts in pharmacokinetics and
pharmacodynamics with application to tumor growth, In: P. Kloedan, C. Potzsche,
eds. Nonautonomous dynamical systems in the life sciences, New York, Springer,
(2013), 225–250.
[24] W. Kelley, A. C. Peterson, Difference Equations: An Introduction with
Applications, Harcourt Academic Press, San Diego, CA, 2001.
[25] G. Koch, A. Walz, G. Lahu, J. Schropp, Modeling of tumor growth and an-
ticancer effects of combination therapy, J. Pharmacokinet Pharmacodyn., 36 (2009),
179–197.
[26] Y. Kwon, Handbook of Essential Pharmacokinetics, Pharmacodynamics and
DrugMetabolism for Industrial Scientists, Springer, New York, (2001).
[27] A. K. Laird, Dynamics of tumor growth, Br. J. Cancer 18, 3 (1964), 490–502.
79
[28] H. Moore, The mathematical and computational sciences special interest group
of the international society of pharmacometrics, CPT Pharmacometrics Syst. Phar-
macol, 8 (2019), 433–435.
[29] I. Podlubny, Fractional-order systems and PIλDν-controllers, IEEE Transac-
tions on Automatic Control, 44 (1999), no. 1, 208–214.
[30] P. Sopasakis, H. Sarimveis, P.Macheras, A. Dokoumetzidis,Fractional
calculus in pharmacokinetics,J. Pharmacokinet Pharmacodyn, 45(1)(2018), 107–
125.
[31] I. Suwan, S. Owies, T. Abdeljawad, Monotonicity results for h–discrete
fractional operators and application, Advances in Difference Equations, 207 (2018),
1–17.
[32] T. Teorell, Kinetics of distribution of substances administered to the body.
I. The extravascular modes of administration, Arch Int Pharmacodyn et Ther
57(1937), 205–225.
[33] D. Verotta, Fractional dynamics pharmacokinetics - pharmacodynamic mod-
els, J. Pharmacokinet Pharmacodyn, 37(3)(2010), 257–276.
[34] T.Zhoroev, Controllability and Observability of Linear Nabla Discrete Frac-
tional Systems, Masters Theses & Specialist Projects. (2019), Paper 3156.
[35] J.G. Wagner, History of pharmacokinetics, Pharmacol. Ther. 12(1981),537–
562
80
